Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: A prospective study

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 7, 2011, Pages 1843-1848

  Dwivedi, Shailendra ^a   Goel, Apul ^a   Natu, Shanker M ^a   Mandhani, Anil ^b   Khattri, Sanjay ^a   Pant, Kamlesh K ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

IL 10; IL 18; Prostate cancer BPH; PSA; ROC curves; Sensitivity; Specificity

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 18; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; DISEASE COURSE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-10; INTERLEUKIN-18; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84864375715     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Abrams S.I. (2004). Role of anti-CTLA-4 therapies in the treatment of cancer. Curr Opinion Mol Ther, 6, 71-7.
2. Cao DY, Yang JY, Dou KF, et al (2007). Alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-cell response from hepatocellular carcinoma patients in vitro. Hum Immunol, 68, 334-41.
3. Curiel T J, Coukos G, Zou L, et al (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10,942-9.
4. De Vita F, Orditura M, Galizia G, et al (2000). Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest, 117,365-73.
5. Enk A H, Jonuleit H, Saloga J, et al (1997). Dendritic cells as mediators of tumor induced tolerance in metastatic melanoma.Int J Cancer, 73, 309-16.
6. Fukuhara H, Ino Y, Kuroda T, et al (2005). Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res, 65, 10663-8.
7. Galizia G, Orditura M, Romano C, et al (2002). Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol, 102, 169-78.
8. Gunel N, Cokun U, Sancak B, et al (2002). Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer, 95, 663-7.
9. Herling M, Rassidakis GZ, Medeiros LJ, et al (2003). Expression of Epstein Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res, 9, 2114-20.
10. Huang M, Stolina M, Sharma S, et al (1998). Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res, 58, 1208-16.
11. Jovasevic V M, Gorelik L, Bluestone J A, et al (2004). Importance of IL- 10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. Immunol, 172, 1449-54.
12. Kawabata T, Ichikura T, Majima T, et al (2001). Prospective serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer, 92, 2050-5.
13. Lebel-Binay S, Berger A, Zinzindohoue F, et al (2000). Interleukin-18: biological properties and clinical implications.Eur Cytokine Netw, 11, 15-26.
14. Loercher A E, Nash M A., Kavanagh JJ, et al (1999). Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cellos'. Immunol, 163, 6251-60.
15. Mapara M Y, Sykes M (2004). Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.J Clin Oncol, 22, 1136-51.
16. Marincola F M, Jaffee E M, Hicklin D J,et al (2000). Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol, 74,181-273.
17. Matar P, Rozados V R, Gervasoni S I, et al (2001). Down regulation of T-cell derived IL-10 production by low-dose cyclo-phosphamide treatment in tumor-bearing rat's restores in vitro normal-lymphoproliferative response. Int Immunopharmacol, 1,307-19.
18. Negrier S, Perol D, Menetrier-Caux C, et al (2004). Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Onco, 22, 2371-8.
19. Pages F, Berger A, Henglein B, et al (1999). Modulation of interleukin -18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer, 84,326-0.
20. Philip H, Amman B, Deborah E, et al (2009). A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urology, 9, 14.
21. Shoujun N, Duangai W, Caibin F, et al (2007). Clinical value of serum interleukin- 18 in patients with prostate cancer. Chinese-German J Clin Oncol, 6, 574-8.
22. Seo N, Hayakawa S, Takigawa M, et al (2001). Interleukin-10 expressed at early tumor sites induces subsequent generation of CD4 (T-regulatory cells and systemic collapse of antitumour immunity. Immunol, 103, 449-57.
23. Seo N, Hayakawa S, Tokura Y (2002). Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells. Semin Cancer Biol, 12, 291-300.
24. Sharma S, Stolina M, Lin Y, et al (1999). T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. Immunol, 163, 5020-8.
25. Specht C, Bexten S, Kolsch E, et al (2001). Prostaglandins, but not tumor-derived IL-10, shut down concomitant tumor-specific CTL responses during murine plasmacytoma progression. Int J Cancer, 91,705-12.
26. Stolina M, Sharma S, Lin Y, et al (2000). Specific inhibition of cyclo- oxygenase 2 restores antitumor-reactivity by alteringthe balance of IL-10 and IL-12 synthesis. J Immunol, 164,361-70.
27. Tanaka F, Hashimoto W, Okamura H, et al (2000). Rapid regeneration of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendrite cells and natural killer cells. Cancer Res, 60, 4838-44.
28. Tsuboi K, Miyazaki T, Nakajima M, et al (2004). Serum IL- 12 and IL-18 levels as tumor marker in patients with oesophageal carcinoma. Cancer Letter, 205, 207-14.
29. Urosevic M, Dummer R (2003). HLA-G and IL-10 expression in human cancer different stories with same message. Semin Cancer Biol, 13, 337-42.
30. Yang L, Carbone D P (2004). Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res, 92, 13-27.